Earnings Scheduled For October 28, 2021
Companies Reporting Before The Bell
• LendingTree (NASDAQ:TREE) is estimated to report quarterly earnings at $0.57 per share on revenue of $292.63 million.
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
Aldeyra Therapeutics Q2 EPS $(0.28) Misses $(0.24) Estimate
Aldeyra Therapeutics (NASDAQ:ALDX) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.24) by 16.67 percent. This is a 12 percent decrease over losses of $(0.25) per share
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate
The FDA has granted orphan drug designation to Aldeyra Therapeutics Inc’s (NASDAQ:ALDX) ADX-2191 to treat retinitis pigmentosa (RP). ADX-2191 is a methotrexate…
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate
The FDA has granted Orphan Drug Designation to Aldeyra Therapeutics Inc’s (NASDAQ:ALDX) ADX-2191 (methotrexate for intravitreal injection) for primary vitreoretinal lymphoma (PVRL). …
Aldeyra Therapeutics FDA AccessData Listing For Co.’s Treatment Candidate For Primary Vitreoretinal Lymphoma Shows Orphan Drug Designation
https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=754320